{"nctId":"NCT02229396","briefTitle":"Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo","startDateStruct":{"date":"2014-09-04","type":"ACTUAL"},"conditions":["Diabetes Mellitus"],"count":695,"armGroups":[{"label":"Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Exantide with Dapagliflozin"]},{"label":"Exenatide Once Weekly 2 mg Alone","type":"EXPERIMENTAL","interventionNames":["Drug: Exentide"]},{"label":"Dapagliflozin Once Daily 10 mg Alone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dapagliflozin"]}],"interventions":[{"name":"Exantide with Dapagliflozin","otherNames":[]},{"name":"Exentide","otherNames":[]},{"name":"Dapagliflozin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Has a diagnosis of T2DM.\n* Has HbA1c of 8.0% to 12.0%, inclusive, at Visit 1 and Visit 2.\n* Treated with a stable dose of metformin ≥1500 mg/day for at least 2 months prior to Screening.\n\nExclusion criteria\n\n* FPG ≥280 mg/dL (15.6 mmol/L).\n* Serum calcitonin concentration ≥40 pg/mL (≥40 ng/L) at Visit 1 (Screening)\n* Clinically significant abnormal free T4 values or patients needing initiation or adjustment of thyroid treatment according to the investigator.\n* Abnormal thyroid stimulating hormone (TSH) value at Screening will be further evaluated by free T4.Patients with clinically significant abnormal free T4 values will be excluded.\n* Known active proliferative retinopathy.\n* History of, or currently have, acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL (≥5.65 mmol/L) at Visit 1\n* History or presence of inflammatory bowel disease or other severe GI diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis.\n* History of gastric bypass surgery or gastric banding surgery, or either procedure is planned during the time period of the study. Current use of gastric balloons is also excluded.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c From Baseline to Week 28","description":"To compare the change from baseline to Week 28 in HbA1c between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":null},{"groupId":"OG001","value":"-1.98","spread":null},{"groupId":"OG002","value":"-1.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 28","description":"To compare the change from baseline to Week 28 in body weight between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":null},{"groupId":"OG001","value":"-3.55","spread":null},{"groupId":"OG002","value":"-1.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose From Baseline to Week 28","description":"To compare the change from baseline to Week 28 in fasting plasma glucose between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.19","spread":null},{"groupId":"OG001","value":"-65.83","spread":null},{"groupId":"OG002","value":"-45.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 28 in 2-hour Postprandial Glucose After a Standard Meal Tolerance Test","description":"To compare the change from baseline to Week 28 in 2-hour postprandial glucose after a standard Meal Tolerance Test between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-61.05","spread":null},{"groupId":"OG001","value":"-87.83","spread":null},{"groupId":"OG002","value":"-60.09","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving Weight Loss ≥5.0% at Week 28","description":"To compare the percentage of patients achieving weight loss ≥5.0% at 28 weeks between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"13.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose From Baseline to Week 2","description":"To compare the change from baseline to Week 2 in fasting plasma glucose between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.31","spread":null},{"groupId":"OG001","value":"-41.34","spread":null},{"groupId":"OG002","value":"-21.08","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Achieving HbA1c <7% at Week 28","description":"To compare the percentage of patients achieving HbA1c \\<7% at 28 weeks between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"44.7","spread":null},{"groupId":"OG002","value":"26.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Week 28","description":"To compare the change from baseline to Week 28 in systolic blood pressure between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"-4.3","spread":null},{"groupId":"OG002","value":"-1.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":233},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Nausea","Injection site nodule","Diarrhoea"]}}}